Latest Breaking News On - Alnylam pharmacauticals - Page 1 : vimarsana.com

This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary am

Rio de janeiroEstado do rioUnited statesNew zealandCidade universitariaAlnylam pharmacauticalsMarques jrClementino fraga filhoWaddington cruzIonis astrazenecaRodolpho paulo roccoIntellia regeneronResearch to practiceAmerican academy of neurology annual meetingIonis pharmaceuticalsIonis pharmaceuticals inc